Omeros Announces Positive OMS721 Data in Model of Age-Related Macular Degeneration

Omeros Corporation (NASDAQ: OMER ) today announced positive data using OMS721, the lead human monoclonal antibody in Omeros' mannan-binding lectin-associated serine protease-2 (MASP-2) program, in a well-established animal model of neovascular age-related macular degeneration (AMD), which is characterized by abnormal growth of new blood vessels behind the retina of